Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug;9(8):e585-e594.
doi: 10.1016/S2352-3018(22)00123-0. Epub 2022 Jul 8.

Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B

Amir M Mohareb  1 , Joseph Larmarange  2 , Arthur Y Kim  3 , Patrick A Coffie  4 , Menan Gérard Kouamé  5 , Anders Boyd  6 , Kenneth A Freedberg  7 , Emily P Hyle  8
Affiliations
Review

Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B

Amir M Mohareb et al. Lancet HIV. 2022 Aug.

Abstract

Individuals with chronic hepatitis B virus (HBV) infection who are at substantial risk of HIV acquisition benefit from pre-exposure prophylaxis (PrEP) with tenofovir-based antiviral therapy. Considering that tenofovir potently inhibits HBV, providing PrEP to individuals with HBV effectively results in treatment of their HBV infection. However, some clinicians might be hesitant to initiate PrEP in people with chronic HBV due to unknown risks of HBV reactivation, hepatitis, and acute liver failure during periods of antiviral cessation. Unfortunately, these knowledge gaps affect scale up of PrEP among people with chronic HBV. Emerging data regarding the risks and benefits of antiviral cessation in people with chronic HBV suggest that PrEP can be safely initiated despite the risks of non-adherence or discontinuation. People with chronic HBV who stop PrEP should be closely monitored for HBV reactivation and hepatitis flares after antiviral cessation.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests We declare no competing interests.

Figures

Figure:
Figure:
HIV Pre-Exposure Prophylaxis (PrEP) and hepatitis B (A) Countries with some form of PrEP program as of March 2022 are in yellow. (B) Model-estimated global prevalence of hepatitis B surface antigen HBsAg (2016). Sources: www.prepwatch.org (an initiative of AVAC: Global Advocacy for HIV Prevention); Polaris Observatory Collaborators. Lancet Gastroenterol Hepatol. 2018; 3: 383–403
See this image and copyright information in PMC

References

    1. Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol 2018; 3: 383–403. - PubMed
    1. World Health Organization, Global Hepatitis Programme. Global hepatitis report, 2017. 2017. Available from: http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?...
    1. Naghavi M, Abajobir AA, Abbafati C, et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet 2017; 390: 1151–210. - PMC - PubMed
    1. Leumi S, Bigna JJ, Amougou MA, Ngouo A, Nyaga UF, Noubiap JJ. Global burden of hepatitis B infection in people living with human immunodeficiency virus: a systematic review and meta-analysis. Clinical Infectious Diseases 2019; published online Dec 9. DOI: 10.1093/cid/ciz1170. - DOI - PubMed
    1. Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009; 49: S138–45. - PubMed

Publication types

MeSH terms